Literature DB >> 25251361

Autism spectrum disorders: a qualitative study of attitudes toward prenatal genetic testing and termination decisions of affected pregnancies.

L S Chen1, L Xu2, S U Dhar2, M Li1, D Talwar1, E Jung1,3.   

Abstract

In the United States, prenatal genetic testing (PGT) for Autism Spectrum Disorders (ASD) is currently available via clinical genetic services. Such testing may inform parents about their unborn child's risk for ASD, prepare parents for the birth of an affected infant, and allow them to arrange for early interventions. Although PGT for autism has potential benefits, the associated ethical, legal, and social implications (ELSI) should be considered. This first qualitative study employed a hypothetical scenario to explore the attitudes toward PGT and termination decisions of 42 parents of children with ASD. Over half of the participants expressed willingness to undergo PGT for autism. Reasons included better preparation for birth, early and better treatment, termination of affected pregnancy, contribution to research, and curiosity. Of the 31 parents who were either willing or unsure about undergoing the PGT, approximately three-fourths would continue their hypothetical affected pregnancies. Explanations included preparation for birth of the child, bonding or acceptance of existing ASD-affected children, apprehensions about test limitations, and religious concerns. Parents who reported they would terminate the affected pregnancy in this hypothetical situation were primarily Asians. This study contributes to the growing understanding of the ELSI aspects of PGT in clinical practice.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autism; parents; prenatal genetic testing; reproductive decisions; termination of pregnancy

Mesh:

Year:  2014        PMID: 25251361     DOI: 10.1111/cge.12504

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

1.  The perception of parents with a child with sickle cell disease in Ghana towards prenatal diagnosis.

Authors:  Menford Owusu Ampomah; Karl Atkin; Kate Flemming
Journal:  J Community Genet       Date:  2022-10-05

2.  Knowledge and Attitudes toward Genetic Testing for Autism Spectrum Disorders among Parents of Affected Children in Taiwan.

Authors:  Ming Li; Shi-Xi Zhao; Wei-Ju Chen; Tse-Yang Huang; Lei-Shih Chen
Journal:  Genes (Basel)       Date:  2022-01-27       Impact factor: 4.096

3.  Genetic Testing Experiences Among Parents of Children with Autism Spectrum Disorder in the United States.

Authors:  Shixi Zhao; Wei-Ju Chen; Shweta U Dhar; Tanya N Eble; Oi-Man Kwok; Lei-Shih Chen
Journal:  J Autism Dev Disord       Date:  2019-12

4.  Attitudes Toward Autism Spectrum Disorders Among Students of Allied Health Professions.

Authors:  Frida Simonstein; Michal Mashiach-Eizenberg
Journal:  J Genet Couns       Date:  2016-06-02       Impact factor: 2.537

5.  Genetic counseling and testing for Asian Americans: a systematic review.

Authors:  Jennifer L Young; Julie Mak; Talia Stanley; Michelle Bass; Mildred K Cho; Holly K Tabor
Journal:  Genet Med       Date:  2021-05-10       Impact factor: 8.822

6.  What Do Parents Think about Chromosomal Microarray Testing? A Qualitative Report from Parents of Children with Autism Spectrum Disorders.

Authors:  Lei Xu; Linda Crane Mitchell; Alice R Richman; Kaitlyn Clawson
Journal:  Autism Res Treat       Date:  2016-06-20

7.  Parents' perceptions of diagnostic genetic testing for children with inherited retinal disease in China.

Authors:  Yu Zhang; Zhirong Wang; Sijian Huang; Limei Sun; Shiying Zhao; Yimin Zhong; Huiming Xiao; Xiaoyan Ding
Journal:  Mol Genet Genomic Med       Date:  2019-08-01       Impact factor: 2.183

8.  Autism Spectrum Disorders: Prenatal Genetic Testing and Abortion Decision-Making among Taiwanese Mothers of Affected Children.

Authors:  Wei-Ju Chen; Shixi Zhao; Tse-Yang Huang; Oi-Man Kwok; Lei-Shih Chen
Journal:  Int J Environ Res Public Health       Date:  2020-01-11       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.